Business Wire

Thales to Provide Mobile Driver Licenses to State of Florida

13.10.2020 16:00:00 EEST | Business Wire | Press release

Share

The State of Florida will be the first state in the United States to provide mobile Driver Licenses with leading-edge security mechanisms, fully compliant with rigorous national and international standards. Thales will supply the Florida Department of Highway Safety and Motor Vehicles with mobile Driver License verification services, as well as a mobile Driver License solution for residents.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201013005021/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

In 2021, Florida residents will be able to apply for new mobile Driver Licenses that are easily accessible on a variety of devices, including smartphones and tablets. These mobile Driver Licenses meet the national and international standards from the American Association of Motor Vehicle Administrators and the International Organization for Standardization, meaning they can be used across the United States and internationally.

These new mobile Driver Licenses have the same validity as traditional driver’s licenses to verify identity, including proof of age and driving privileges. It also provides an additional role as a strong authentication tool, enabling Floridians to securely prove who they are online for a variety of services.

Now, to complement the traditional use of driver licenses to prove their identity, Florida residents will be able to simply activate their mobile identification application, select the type of verification needed, and hold up their mobile device. The mobile device never leaves the owners hand, making it a contact-free and convenient way to show ID.

“I’m excited for this innovation project that will make the state of Florida a national leader in offering secure and trusted mobile identification, which is a priority for our Governor, Ron DeSantis,” said Terry L. Rhodes, Executive Director of the Florida Department of Highway Safety and Motor Vehicles. “We have made a sustained commitment to the modernization of nearly every aspect of what our department does and how customers access our services, and Thales will be a great partner as Florida now steps into the future of mobile identification.”

“As ID fraud becomes more frequent and sophisticated, we made it a priority to reinforce ID verification by adding extra software security technologies. In the future, enterprises such as airports, hotels, car rental companies etc, in Florida will be able to rely on Thales to identify customers, while guaranteeing their privacy”, said Tony Lo Brutto, VP NORAM, Identity and Biometric Solutions at Thales.

These mobile Driver Licenses are harder to counterfeit, as they host a secure digitized credential whose authenticity can be checked rather than simply displaying a digital image of a driver license that could be easily manipulated.

For stronger privacy, users of mobile Driver Licenses control what information is displayed from the app depending on the context. For example, to enter a casino it only needs to show that the individual is old enough and the mobile Driver License will just display that information – not the individual’s name, date of birth, or address.

The Florida mobile Driver License program builds on Thales’ strong foundation of supporting state identity programs for 11 other U.S. states and five Canadian provinces.

Note to Editors

Thales, a leader in mobile driver’s license technology, successfully conducted the first U.S. mobile Driver’s License or Digital Driver’s License pilots across multiple states through a partnership and grant awarded in 2016 by the U.S. National Institute of Standards and Technology. Thales has recently been nationally recognized for the Digital ID Wallet, which incorporates the mobile Driver’s License solution, by Frost & Sullivan and ABI Research

About Thales

Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019.

Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.

PLEASE VISIT
Thales Group
Download HD pictures

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS CONTACT
Thales, Media Relations

Digital Identity & Security
Vanessa Viala
+33 6 07 34 00 34
Vanessa.viala@thalesgroup.com

Thales, Media Relations
USA
Adam Kostecki
+1 (703) 838-5645
adam.kostecki@us.thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye